ALLMedicine™ Hyperkalemia Center

Feb 23rd, 2021 - Introduction: Patients with cardiovascular diseases (CVD) are at increased risk of hyperkalemia, particularly when treated with renin-angiotensin-aldosterone inhibitors (RAASIs). Because the occurrence or fear of hyperkalemia, RAASIs are frequentl...

Feb 20th, 2021 - The optimal ambulatory management of renin-angiotensin-aldosterone system inhibitor (RAASi)-related hyperkalemia to reduce the risk of recurrence is unknown. We examined the risk of hyperkalemia recurrence on the basis of outpatient pharmacologic ...

Feb 19th, 2021 - Severe hyperkalemia can cause life-threatening arrhythmia, cardiac arrest, or death. This study aimed to investigate the incidence and the associated factors relevant to critical hyperkalemia (≥6 mmol/L) among inpatients, outpatients, and emergenc...

Feb 18th, 2021 - Renin-angiotensin-aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). Howev...

Feb 15th, 2021 - Chronic kidney disease (CKD) contributes to hypertension, but the mechanisms are incompletely understood. To address this, we applied the 5/6th nephrectomy rat model to characterize hypertension and the response to dietary salt and renin-angiotens...

Feb 23rd, 2021 - Introduction: Patients with cardiovascular diseases (CVD) are at increased risk of hyperkalemia, particularly when treated with renin-angiotensin-aldosterone inhibitors (RAASIs). Because the occurrence or fear of hyperkalemia, RAASIs are frequentl...

Feb 20th, 2021 - The optimal ambulatory management of renin-angiotensin-aldosterone system inhibitor (RAASi)-related hyperkalemia to reduce the risk of recurrence is unknown. We examined the risk of hyperkalemia recurrence on the basis of outpatient pharmacologic ...

Feb 19th, 2021 - Severe hyperkalemia can cause life-threatening arrhythmia, cardiac arrest, or death. This study aimed to investigate the incidence and the associated factors relevant to critical hyperkalemia (≥6 mmol/L) among inpatients, outpatients, and emergenc...

Feb 18th, 2021 - Renin-angiotensin-aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). Howev...

Feb 16th, 2021 - Hydrochloro­thiazide capsules USP are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combina­tion diuretic products, hydrochloro­thiazide c...

Oct 28th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Oct 28th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Oct 22nd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

Oct 22nd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

Sep 3rd, 2020 - Mineralocorticoid receptor antagonists (MRAs) are still finding their place in nephrology. Many of us relegate them to the bottom of our therapeutic bag for use only after we've exhausted other renin-angiotensin-aldosterone (RAAS)-modifying agents...